EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis

Tim A C de Vries iD, Imaad U Mallick iD, Vinai C Bhagirath, John W Eikelboom, Calvin Gomes, Qilong Yi, Sean McGrath iD, Jack Hirsh, Noel C Chan iD

Thrombosis and Haemostasis · 2025-06 · 125 (06) · 563-573

DOI: 10.1055/a-2446-1348 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 21.11.2024. Verfasst von Tim A C de Vries und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Cardiology and Cardiothoracic Surgery, Amsterdam University Medical Centers, University of Amsterdam, Amsterd…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Stroke, Factor Xa Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation Graduate Research Fellowship Program, Heart and Stroke of Canada New Investigator Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although most patients with atrial fibrillation (AF) receiving a direct oral anticoagulant (DOAC) do not require drug concentration measurements, there are situations where such information could be useful. Existing guidance documents provide usual on-therapy ranges for drug concentrations, but these have important limitations. This is a systematic review and meta-analysis of studies reporting trough and peak levels of DOAC regimens approved for stroke prevention in AF. We used random effects models and the quantile estimation method to estimate the median and a usual on-therapy range (10th and 90th percentiles). Of 4,822 unique publications, 53 studies met eligibility (29,266 trough and 12,103 peak levels). Usual on-therapy ranges for trough levels were 38 to 155 and 58 to 206 ng/mL for apixaban 2.5 and 5 mg twice daily; 35 to 138 and 33 to 151 ng/mL for dabigatran 110 and 150 mg twice daily; 8 to 54 and 13 to 66 ng/mL for edoxaban 30 and 60 mg daily; and 16 to 74 and 19 to 72 ng/mL for rivaroxaban 15 and 20 mg daily. The corresponding range for peak levels were 96 to 251 and 132 to 343; 65 to 223 and 76 to 285; 57 to 219 and 127 to 407; 131 to 384, and 169 to 313 ng/mL, respectively. This systematic review and meta-analysis provides updated and more representative usual on-therapy ranges of DOAC levels in patients with AF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsStrokeFactor Xa InhibitorsHumansAdministration, OralPyridonesDabigatranRivaroxabanPyrazolesDrug MonitoringPyridinesThiazoles

Substanzen

AnticoagulantsPyridonesapixabanDabigatranRivaroxabanFactor Xa InhibitorsPyrazolesedoxabanPyridinesThiazoles

Autor:innen und Institutionen

  • Department of Clinical and Experimental Cardiology and Cardiothoracic Surgery, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam, The Netherlands.
  • Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
  • Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands.
  • School of Medicine, St. George's University, Grenada, West Indies.
  • Division of Hematology and Thromboembolism, Department of Medicine, Population Health Research Institute, Hamilton, Ontario, Canada.

ORCID-Profile: Tim A C de Vries, Imaad U Mallick, Sean McGrath, Noel C Chan

Förderung

  • National Science Foundation Graduate Research Fellowship Program
  • Heart and Stroke of Canada New Investigator Award

Zitieren

APA

de Vries, T. A. C., Mallick, I. U., Bhagirath, V. C., Eikelboom, J. W., Gomes, C., Yi, Q., McGrath, S., Hirsh, J., & Chan, N. C. (2025). Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. Thrombosis and Haemostasis, 125(06), 563-573. https://doi.org/10.1055/a-2446-1348

Vancouver

de Vries TAC, Mallick IU, Bhagirath VC, Eikelboom JW, Gomes C, Yi Q, et al. Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. Thrombosis and Haemostasis. 2025;125(06):563-573. doi:10.1055/a-2446-1348

BibTeX
@article{deVries2025,
  author = {de Vries, Tim A C and Mallick, Imaad U and Bhagirath, Vinai C and Eikelboom, John W and Gomes, Calvin and Yi, Qilong and McGrath, Sean and Hirsh, Jack and Chan, Noel C},
  title = {Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {06},
  pages = {563--573},
  doi = {10.1055/a-2446-1348}
}
Kostenlos starten →